Download PDF
Aktuelle Dermatologie
DOI: 10.1055/a-2261-9018
Übersicht

Alopecia areata – ein Update

Alopecia areata – an update
Stephanie Marie Huber
1   Dermatologische Klinik, Universitätsspital Basel, Basel, Schweiz
,
Alexander A. Navarini
1   Dermatologische Klinik, Universitätsspital Basel, Basel, Schweiz
,
Ralph P. Braun
2   Dermatologische Klinik, UniversitätsSpital Zürich, Zürich, Schweiz
,
Christian Greis
2   Dermatologische Klinik, UniversitätsSpital Zürich, Zürich, Schweiz
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Alopecia areata (AA) – der kreisrunde Haarausfall – stellt nach der androgenetischen Alopezie die zweithäufigste Haarverlusterkrankung weltweit dar. Es wird vermutet, dass es infolge des Verlusts des Immunprivilegs des Haarfollikels zu einer Destruktion der Zellen des Haarfollikels kommt. Der konsekutive Haarausfall geht mit erheblichen Auswirkungen auf die Lebensqualität einher. Die Spontanremission liegt insbesondere bei leichteren Verlaufsformen bei bis zu 80%. Es bestehen topische, injizierbare und systemische immunsupprimierenden bzw. -modulierende Behandlungsmöglichkeiten. Vielversprechend scheinen v.a. systemisch verabreichte JAK-Inhibitoren zu sein.

Abstract

Alopecia areata (AA) – circular hair loss – is the second most common hair loss disease worldwide after androgenetic alopecia. It is assumed that the loss of the immune privilege of the hair follicle leads to the destruction of the cells of the hair follicle. The consecutive hair loss is associated with considerable effects on quality of life. The spontaneous remission rate, especially in milder forms, can be up to 80%. There are topical, injectable, and systemic immunosuppressive or immunomodulating treatment options available. Systemically administered JAK inhibitors appear to be particularly promising.



Publication History

Article published online:
13 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Yousaf A, Lee J, Fang W. et al. Association Between Alopecia Areata and Natural Hair Color Among White Individuals. JAMA Dermatol 2021; e210144
    PubMedGoogle Scholar
  • 2 Tu TY, Chang R, Lai JN. et al. Human papillomavirus symptomatic infection associated with increased risk of new-onset alopecia areata: A nationwide population-based cohort study. J Autoimmun 2021; 119: 102618
    CrossrefPubMedGoogle Scholar
  • 3 Dai YX, Yeh FY, Shen YJ. et al. Cigarette Smoking, Alcohol Consumption, and Risk of Alopecia Areata: A Population-Based Cohort Study in Taiwan. Am J Clin Dermatol 2020; 21: 901-911
    CrossrefPubMedGoogle Scholar
  • 4 Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol 2018; 57: 776-783
    CrossrefPubMedGoogle Scholar
  • 5 Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med 2022; 54: 694-712
    CrossrefPubMedGoogle Scholar
  • 6 Ovcharenko Y, Serbina I, Zlotogorski A. et al. Renbök phenomenon in an alopecia areata patient with psoriasis. Int J Trichology 2013; 5: 194-195
    CrossrefPubMedGoogle Scholar
  • 7 Olsen E, Hordinsky M, McDonald-Hull S. et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999; 40: 242-246
    CrossrefPubMedGoogle Scholar
  • 8 Gudobba C, Mane T, Bayramova A. et al. Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores. JAMA Dermatol 2023; 159: 143-150
    CrossrefPubMedGoogle Scholar
  • 9 Rudnicka L, Olszewska M, Rakowska A. Atlas of Trichoscopy. London: Springer; 2012
    CrossrefGoogle Scholar
  • 10 Kempf W, Hantschke M, Kutzner H. et al. Dermatopathologie. Berlin: Springer; 2020
    CrossrefGoogle Scholar
  • 11 Nomiyama T, Katoh N. Clobetasol propionate 0.05% under occlusion for alopecia areata: Clinical effect and influence on intraocular pressure. Australas J Dermatol 2021; 62: e262-e264
    CrossrefPubMedGoogle Scholar
  • 12 Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52: 138-139
    CrossrefPubMedGoogle Scholar
  • 13 Yee BE, Tong Y, Goldenberg A. et al. Efficacy of different concentrations of intral­esional triamcinolone acetonide for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol 2020; 82: 1018-1021
    CrossrefPubMedGoogle Scholar
  • 14 Rastaghi F, Kaveh R, Yazdanpanah N. et al. The Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata: A Review Article. Dermatol Pract Concept 2023; 13: e2023255
    CrossrefPubMedGoogle Scholar
  • 15 Fukumoto T, Fukumoto R, Magno E. et al. Treatments for alopecia areata: A systematic review and network meta-analysis. Dermatol Ther 2021; 34: e14916
    CrossrefPubMedGoogle Scholar
  • 16 King B, Ohyama M, Kwon O. et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med 2022; 386: 1687-1699
    CrossrefPubMedGoogle Scholar
  • 17 King B, Guttman-Yassky E, Peeva E. et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol 2021; 85: 379-387
    CrossrefPubMedGoogle Scholar
  • 18 Peeva E, Guttman-Yassky E, Banerjee A. et al. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol 2022; 87: 390-393
    CrossrefPubMedGoogle Scholar
  • 19 Dai Z, Chen J, Chang Y. et al. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight 2021; 6: 142205
    CrossrefPubMedGoogle Scholar
  • 20 Dhurat R, Sharma R. A Practical Approach to the Treatment of Alopecia Areata. Indian Dermatol Online J 2022; 13: 725-728
    PubMedGoogle Scholar
  • 21 Roohaninasab M, Goodarzi A, Ghassemi M. et al. Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. Dermatol Ther 2021; 34: e14768
    CrossrefPubMedGoogle Scholar
  • 22 Cruciani M, Masiello F, Pati I. et al. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfus 2023; 21: 24-36
    PubMedGoogle Scholar